NextCure goes all in on B7-H4, stopping other programs to challenge Big Pharma in ADC space

NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). The biotech has decided to seek partners for its existing clinical candidate and other preclinical programs to free up cash for its new priority.